Prognostic value of somatosensory evoked potentials, @entity3508 , and XXXX for short-term outcome in @entity385 .

@entity1 @entity64 @entity2500 @entity2286 @entity4483 @entity52220 @entity3508 @entity385
To predict short-term outcome in acute @entity385 , we analyzed somatosensory evoked potentials ( @entity52220 ) and biochemical parameters [ @entity3508 ( @entity3508 ) and @entity4483 protein] in a prospective study with serial measurement. In 31 @entity1 with 1st @entity2500 , serum @entity3508 and @entity4483 protein were measured daily between days 1 and 6 poststroke. The N20 and N70 components of the @entity52220 (SEP20 and SEP70) were determined on days 1 and 6. @entity52220 and biochemical markers in @entity64 @entity1 were compared with a control group. Short-term outcome was assessed by the modified Rankin Scale (mRS) at days 7-10 and was dichotomized between good (mRS 0-2) and poor (mRS >= 3) outcome. Specificity and positive predictive value ( @entity2286 ) were high at day 1 for @entity52220 (SEP20: 100% for both; SEP70: 93 and 88%, respectively) compared with lower values for @entity3508 (67 and 50%) and @entity4483 (23 and 57%). In contrast, @entity4483 showed the highest sensitivity at day 1 with 77% compared with a relatively low sensitivity of @entity3508 (31%) and @entity52220 (SEP20: 35%, SEP70: 47%). The biochemical markers showed an improving sensitivity over time with best values (>90%) between days 3 and 4 at the expense of a lower specificity. Specificity and @entity2286 of @entity52220 on day 6 was still 100% with sensitivity increasing up to 53% (SEP20) and 60% (SEP70). @entity52220 could early differentiate between good and poor outcome and reliably predict poor outcome. Since biochemical markers and @entity52220 complement each other in the prognosis of @entity64 , a combined application of these markers seems promising.
